At a glance
ClinicalIndex Comparison Record- ✓Current LVAD implantation
- ✓Not already prescribed an SGLT2i
- ✓Adequate kidney function (eGFR ≥30 ml/min/1.73 m²)
- ✓Age ≥18 years
- ✕Type 1 diabetes mellitus
- ✕eGFR <30 ml/min/1.73 m² (severely reduced kidney function)
- ✕Age <18 years
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Heart Failure Patients With Left Ventricular Assist Devices Being Treated With Sodium-Glucose Co-Transporter 2 Inhibitors
In Brief
A Phase 4 clinical trial evaluating SGLT2i and No SGLT2i for Heart Failure With Reduced Ejection Fraction. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
Study Details
Timeline
Arms & Interventions
Participants will be asked to take an SGLT2i for 6 months. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
Participants will not be asked to take an SGLT2i. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
Interventions
empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage
No SGLT2i